Current Urology Reports最新文献_第2页

Artificial Intelligence for Clinical Management of Male Infertility, a Scoping Review. 人工智能在男性不育症临床治疗中的应用，范围综述。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-11-09 DOI: 10.1007/s11934-024-01239-z

Noopur Naik, Bradley Roth, Scott D Lundy

{"title":"Artificial Intelligence for Clinical Management of Male Infertility, a Scoping Review.","authors":"Noopur Naik, Bradley Roth, Scott D Lundy","doi":"10.1007/s11934-024-01239-z","DOIUrl":"10.1007/s11934-024-01239-z","url":null,"abstract":"Purpose of review: Infertility impacts one in six couples worldwide, with male infertility contributing to approximately half of these cases. However, the causes of infertility remain incompletely understood, and current methods of clinical management are cost-restrictive, time-intensive, and have limited success. Artificial intelligence (AI) may help address some of these challenges. In this review, we synthesize recent literature in AI with implications for the clinical management of male infertility.Recent findings: Artificial intelligence may offer opportunities for proactive, cost-effective, and efficient management of male infertility, specifically in the areas of hypogonadism, semen analysis, and interventions such as assisted reproductive technology. Patients may benefit from the integration of AI into a male infertility specialist's clinical workflow. The ability of AI to integrate large volumes of data into predictive models could help clinicians guide conversations with patients on the value of various treatment options in infertility, but caution must be taken to ensure the quality of care being delivered remains high.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":"26 1","pages":"17"},"PeriodicalIF":2.5,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Voiding Dysfunction in Transgender Patients: What We Know and What We Do Not Know. 变性患者的排尿功能障碍：我们知道什么，我们不知道什么。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-11-05 DOI: 10.1007/s11934-024-01234-4

Gabriela Gonzalez, Jennifer T Anger

{"title":"Voiding Dysfunction in Transgender Patients: What We Know and What We Do Not Know.","authors":"Gabriela Gonzalez, Jennifer T Anger","doi":"10.1007/s11934-024-01234-4","DOIUrl":"10.1007/s11934-024-01234-4","url":null,"abstract":"Purpose of review: Transgender and non-binary patients (TGNB) undergoing gender affirming genital surgery may experience perioperative voiding dysfunction. This review aims to outline and analyze literature about gender affirming pelvic surgery urinary complications, evaluation, and treatment.Recent findings: If a patient is seeking bottom surgery, then urinary goals and pre-operative symptoms should be discussed with respect to variable post-operative outcomes. Urologists should also be aware of the effect that gender affirming hormone therapy has on urinary symptoms. Urethral strictures and urethrocutaneous fistulae occur after feminizing and masculinizing procedures and may manifest as LUTS. Although there is no standardized approach for managing post-operative voiding issues, we present available options. The evaluation of TGNB patients is ideally affirming and tailored to the patient. Long-term urinary and voiding outcomes measurements after vaginoplasty and phalloplasty are also needed, as current validated questionnaires do not capture these symptoms well in TGNB patients.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":"26 1","pages":"16"},"PeriodicalIF":2.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Focal Therapy in Grade Group 3 Prostate Cancer. 3级前列腺癌的局部治疗

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-11-01 Epub Date: 2024-07-02 DOI: 10.1007/s11934-024-01211-x

Lee Pressler, Mariel Pressler

{"title":"Focal Therapy in Grade Group 3 Prostate Cancer.","authors":"Lee Pressler, Mariel Pressler","doi":"10.1007/s11934-024-01211-x","DOIUrl":"10.1007/s11934-024-01211-x","url":null,"abstract":"Purpose of this review: Treatment of intermediate risk prostate cancer remains controversial. Clearly some patients with low volume favorable intermediate risk can be followed with active surveillance. Those with high volume bilateral disease need more radical whole gland therapy. The question remains on how to best treat low volume localized unfavorable intermediate risk prostate cancer (GG3) while maintaining quality of life. Focal therapy has been becoming a popular option for many patients with localized prostate cancer. Most studies looking at focal therapy for prostate cancer have been limited to GG1 and GG2, many of whom may not need treatment. We set out to review the literature evaluating the safety and efficacy of focal therapy for GG3 prostate cancer.Recent findings: We reviewed multiple peer review articles obtained from a PubMed search. While in field biopsy recurrence rates approach 20%, failure free survival and overall survival exceeds 90%. While focal therapy for unfavorable GG3 intermediate risk prostate cancer may have higher rates of local recurrence with appropriate post procedure follow up, patients who need salvage therapy are easily identified and survival rates are very high. Focal therapy is a good option for patients with localized low volume GG3 prostate cancer without compromising cancer survival and preserving quality of life.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":" ","pages":"271-275"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11366723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling the Complexities of Uretero-Enteric Strictures: A Modern Review. 解读输尿管-肠管狭窄的复杂性：现代回顾。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-14 DOI: 10.1007/s11934-024-01222-8

A Abdalla, Joshua A Cohn, J Simhan

引用次数: 0

Functional Outcomes of Orthotopic Neobladder in Women. 女性矫形新膀胱的功能结果。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-28 DOI: 10.1007/s11934-024-01223-7

Unwanaobong Nseyo, David Ginsberg

{"title":"Functional Outcomes of Orthotopic Neobladder in Women.","authors":"Unwanaobong Nseyo, David Ginsberg","doi":"10.1007/s11934-024-01223-7","DOIUrl":"10.1007/s11934-024-01223-7","url":null,"abstract":"Purpose of review: This review paper summarizes the available literature on the evolution of surgical approach to radical cystectomy in female bladder cancer patients and its impact on functional outcomes in orthotopic neobladder.Recent findings: Traditionally, radical cystectomy in female bladder cancer patients has been maximally extirpative with pelvic exenteration. Recently, new techniques which include pelvic organ-sparing, nerve-sparing and vaginal-sparing have demonstrated improved rates of urinary incontinence and retention. Additional techniques include prophylactic apical suspension which reduces the likelihood of pelvic organ prolapse, a risk factor for voiding dysfunction in the setting of orthotopic neobladder. Surgical management of bladder cancer in female patients has evolved to include surgical approaches which center quality of life and functional outcomes that are unique to female patients who have undergone radical cystectomy with ileal neobladder and can be optimized based on considerations regarding an approach that limits pelvic floor and pelvic nerve disruption.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":" ","pages":"277-285"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11366725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142092520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Telemedicine in Endourology for Patient Management and Healthcare Delivery: Current Status and Future Perspectives. 远程医疗在腔内泌尿学中用于患者管理和医疗服务：现状与未来展望》。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-11-01 Epub Date: 2024-07-09 DOI: 10.1007/s11934-024-01224-6

Ali Talyshinskii, Nithesh Naik, B M Zeeshan Hameed, Gafour Khairley, Princy Randhawa, Bhaskar Kumar Somani

{"title":"Telemedicine in Endourology for Patient Management and Healthcare Delivery: Current Status and Future Perspectives.","authors":"Ali Talyshinskii, Nithesh Naik, B M Zeeshan Hameed, Gafour Khairley, Princy Randhawa, Bhaskar Kumar Somani","doi":"10.1007/s11934-024-01224-6","DOIUrl":"10.1007/s11934-024-01224-6","url":null,"abstract":"Purpose of review: Researchers have examined how telemedicine affects endourological patients. This review analyzes the literature to determine telemedicine's benefits and limitations in endourology.Recent findings: Many studies were devoted to describing the effect of telemedicine on endourological patient satisfaction, optimization of the clinical decision-making among patients with kidney and ureteric stones, the effectiveness of telemedicine in the management of patients with indications for PCNL, follow-up for patients with urolithiasis and describing financial effectiveness for the patients after BOO surgery. The authors describe phone calls, video calls, and online booking platforms as used as telemedicine technology. However, several concerns also exist, such as the necessity of internet connections and appropriate devices, different receptivity among certain subgroups, data safety, and different regulatory environments among countries. Telemedicine offers the potential to reduce patient travel time, expedite decision-making, and save costs in endourology. However, its everyday implementation is challenging due to various obstacles faced by patients and providers, hindering the realization of its full potential and necessitating a systematic approach to problem-solving.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":" ","pages":"299-310"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11366724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and Future Directions of Technology in Assessment of Peyronie's Disease. 评估佩罗尼氏病的当前和未来技术发展方向。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-29 DOI: 10.1007/s11934-024-01247-z

Abrar H Mian, Matthew J Ziegelmann

{"title":"Current and Future Directions of Technology in Assessment of Peyronie's Disease.","authors":"Abrar H Mian, Matthew J Ziegelmann","doi":"10.1007/s11934-024-01247-z","DOIUrl":"10.1007/s11934-024-01247-z","url":null,"abstract":"Purpose of review: This review assesses the effectiveness of various imaging modalities for diagnosing and managing Peyronie's disease (PD), exploring their clinical utility and limitations.Recent findings: Ultrasonography, currently the only modality endorsed by the American Urological Association, effectively detects calcifications and assesses vascular status but struggles with identifying non-palpable plaques. Computed tomography and magnetic resonance imaging provide detailed anatomical views but are costly along with other deterring factors. Autophotography and 3-dimensional imaging offer convenient home assessments but with variable accuracy. Elastography improves upon traditional ultrasonography, while emerging AI technologies show promise for automating precise curvature assessments, pending further validation. A combined approach tailored to each individual patient based on their needs enhances diagnostic accuracy. Supplementing ultrasonography with elastography and potentially AI could improve diagnostic outcomes and better guide treatment decisions. Continued research is vital to integrate these advancements into standard clinical practice and develop updated standardized protocols.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":"26 1","pages":"15"},"PeriodicalIF":2.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Intersection of Artificial Intelligence, Wearable Devices, and Sexual Medicine. 人工智能、可穿戴设备和性医学的交叉点。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-11 DOI: 10.1007/s11934-024-01244-2

Dayna R Smerina, Amy M Pearlman

引用次数: 0

Strategies to Improve Clinical Outcomes and Patient Experience Undergoing Transurethral Resection of Bladder Tumor. 改善经尿道膀胱肿瘤切除术临床效果和患者体验的策略。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-11 DOI: 10.1007/s11934-024-01243-3

Sadra Sepehri, Michael E Rezaee, Zhuo Tony Su, Max Kates

{"title":"Strategies to Improve Clinical Outcomes and Patient Experience Undergoing Transurethral Resection of Bladder Tumor.","authors":"Sadra Sepehri, Michael E Rezaee, Zhuo Tony Su, Max Kates","doi":"10.1007/s11934-024-01243-3","DOIUrl":"https://doi.org/10.1007/s11934-024-01243-3","url":null,"abstract":"Purpose of review: To describe patient experiences of transurethral resection of bladder tumor (TURBT) and review recent advances in enhancing clinical outcomes.Recent findings: High rates of recurrence and progression of non-muscle invasive bladder tumors expose patients to multiple TURBT procedures throughout their disease process. Understanding the impact of TURBT on quality of life and patient experiences is crucial for shared decision-making, thus enhanced recovery protocol trials are being explored to improve patient outcomes. The variability in TURBT practices worldwide contributes to differing bladder tumor recurrence rates, prompting efforts to standardize practices by evaluating the impact of patient, hospital, and surgeon factors. For select cases, less intensive surveillance regimens have reduced toxicities and costs without compromising oncologic outcomes. New innovative approaches such as en bloc- and stratified resection techniques may reduce perioperative complications and improve clinical outcomes. Finally, neoadjuvant and ablative treatments have shown to be promising alternatives to TURBT, necessitating further investigation in this setting. TURBT is essential for diagnosing and treating bladder cancer. Reducing associated morbidities and improving surgical outcomes involve multifaceted approaches, including standardizing surgical practices, exploring innovative techniques, and optimizing surveillance regimens, all while promoting patient quality of life. Neoadjuvant therapies as alternative treatments are on the horizon and may ultimately change the landscape of bladder cancer care.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":"26 1","pages":"13"},"PeriodicalIF":2.5,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer. DNA 修复缺陷在不断变化的膀胱癌治疗中的影响。

IF 2.5 2区医学

Current Urology Reports Pub Date : 2024-10-09 DOI: 10.1007/s11934-024-01242-4

Vincent D D'Andrea, Christopher J Magnani, John Ernandez, Joaquim Bellmunt, Matthew Mossanen, Timothy N Clinton, Filipe L F Carvalho, Kent W Mouw

{"title":"Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer.","authors":"Vincent D D'Andrea, Christopher J Magnani, John Ernandez, Joaquim Bellmunt, Matthew Mossanen, Timothy N Clinton, Filipe L F Carvalho, Kent W Mouw","doi":"10.1007/s11934-024-01242-4","DOIUrl":"https://doi.org/10.1007/s11934-024-01242-4","url":null,"abstract":"Purpose of review: This review explores the current landscape of treatments which target the DNA damage response (DDR) in metastatic and muscle-invasive bladder cancer. It emphasizes recent clinical trials which integrate DDR inhibitors with standard chemotherapy and immunotherapy.Recent findings: Noteworthy findings include the ATLANTIS trial, which demonstrated prolonged progression-free survival (PFS) in DDR biomarker-selected patients using PARP inhibitors as maintenance after standard chemotherapy. Trials such as BAYOU, which combined immunotherapy with PARP inhibition, similarly suggested a potential therapeutic benefit in DDR biomarker-selected patients with bladder cancer. Efforts to develop bladder-sparing treatment regimens based on DDR-associated mutational profiles, such as the RETAIN and HCRN 16-257 trials, have had mixed outcomes to date. There are now ongoing efforts to combine DDR inhibitors with the newest bladder cancer therapies, such as antibody-drug conjugates. This review highlights the most recent advances in targeting DNA repair deficiency in the evolving treatment landscape of bladder cancer.","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":"26 1","pages":"12"},"PeriodicalIF":2.5,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0